Clinical Trial Update: A2-ESO-1 TCR-Engineered T Cells for Relapsed/Refractory Advanced or Metastatic NY-ESO-1 Overexpression Positive Triple Negative Breast Cancer [Phase 1]

View source ↗

Summary

A Phase 1 trial of A2-ESO-1 TCR-Engineered T Cells for NY-ESO-1 overexpression positive triple negative breast cancer has been suspended. The status update indi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• A2-ESO-1 TCR-Engineered T Cells

Snippet

Sponsor: University of Southern California | Conditions: Triple Negative Breast Cancer | Phase 1 | Status: SUSPENDED